肺鳞癌患者ERCC1蛋白表达与顺铂体外药敏相关性的研究  

Study on the relationship between ERCC1 protein expression and sensitivity of squamous-cell lung carcinomas to cisplatin in vitro

作　　者：周伟华[1] 邓觐云[2] 黄传生[2] 李张云[2] 陈悦[2] 

机构地区：[1]南昌大学医学院,南昌330006 [2]江西省肿瘤医院,南昌330029

出　　处：《江西医药》2009年第4期299-301,共3页Jiangxi Medical Journal

摘　　要：目的探讨肺鳞癌组织切除修复交叉互补基因1(ERCC1)蛋白表达与顺铂体外药敏的关系。方法用ATP-TCA法对42例肺鳞癌患者手术切除的新鲜标本进行顺铂体外药敏检测,并用免疫组织化学检测其ERCC1蛋白表达,比较分析ERCC1表达与顺铂疗效的关系。结果ERCC1阳性表达22例(52.4%),阴性表达20例(47.6%);结合顺铂体外药敏结果得出,阳性表达组顺铂有效为8例(36.7%);阴性表达组有效14例(70%),即ERCC1阴性表达对顺铂的体外疗效明显优于阳性表达组,(P<0.05)。结论ERCC1有望成为以顺铂为治疗基础的肺鳞癌患者的预测指标。Objective To determine the relationship between ERCC1 protein expression and sensitivity of squamous-cell lung carcinomas to cisplatin in vitro.Methods Tested the sensitivity of 42 operative fresh squamous-cell lung carcinomas tissues to cisplatin with the method of ATP-TCA;The level of ERCC1 was detected by means of immunohistochemistry ,and then analyze the relation between the expression of ERCC1 and chemosensitivity of cisplatin.Resuits There were 22 （52.4%） eases with ERCCl-positive, and still another 20 （47.6%） cases with ERCC1-negative.On the basis of ATP-TCA assay,we can learned that there were 8 （36.7%） cases with sensitve to cisplatin in the ERCCl-positive group,and 14（70%） sensitive cases in the ERCCl-negative group, A benefit from cisplatin chemotherapy was associated with the absence of ERCC1 （P〈0.05）.Conclution ERCC1 may be an useful prognostic marker in patients with squamous-cell lung cancer treated with cisplatin-based chemotherapy.

关 键 词：肺鳞癌 切除修复交叉互补基因1(ERCC1) 顺铂 ATP生物荧光法 耐药 

分 类 号：R734.2[医药卫生—肿瘤]